KALY Publishes Cannabis Extract COPD Treatment Study Report
March 22 2019 - 9:47AM
InvestorsHub NewsWire
KALY Publishes Cannabis Extract
COPD Treatment Study Report
Dallas, TX -- March 22, 2019 -- InvestorsHub
NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts,
Inc.) (USOTC:
KALY) (“KALY”) today published the research report on the
recent pilot treatment of Chronic
Obstructive Pulmonary Disease (COPD) in primates using an
extract derived from KALY’s patented cannabis extraction
process. The report details the study method and the
significance of the study. The report includes specific
findings and due to the substantial findings, the report includes
guidelines for next stage tests.
“These
preliminary studies were designed to begin assessment of the
relative efficacy of NCMB-1 compound on pulmonary of in the AGM
previously treated to induce a fixed level of airway fibrosis. The
overall results demonstrate that NCMB-1 improved airway function as
measured by increased tidal volume, increased airway flow and hence
decreased airway resistance and increased respiration
rate.”
“Given the in vitro studies previously conducted
in cultured human pulmonary epithelial cells, the role of
anti-inflammatory agents and their genetic regulation are a clear
target for the continued study of the AGM and pulmonary functional
responses to NCMB-1.”
The full report can be read on the company’s
website at www.kali-extracts.com.
KALY is a health and wellness company set to
generate revenue from its patented cannabis extraction technology
through overlapping go-to-market strategies. In addition
developing pharmaceutical products internally and through
partnerships, KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. The first revenue generating contracts signed
in December of 2018 will be reflected in the company’s upcoming
annual report.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024